Cingulate Inc. (CING)
Last updated: 2026-10-21 20:05:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Summary
Cingulate Inc. (CING) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.66, with a market capitalization of $63.40M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.16 to $11.89. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$63.40M | |
$4.53 | |
$1,236.00 | |
$1.80 | |
$4.53 | |
128.18K | |
119.94K | |
-- | |
$11.89 | |
$3.16 | |
-- | |
-- |
Cingulate Inc. (CING) After-Hours Stock Price
Cingulate Inc. (CING) is trading at $4.66 in after-hours trading as of 2026-10-21 20:01:00, up 2.89% ($0.13) from the regular-session close of $4.53.
After-hours trading shows how investors are pricing CING after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Cingulate Inc. (CING) 7-Day Stock Price Change
Over the past seven days, Cingulate Inc. (CING) moved from $4.84 to $4.66, representing a decline of 3.66% ($0.18).
The stock traded between $4.12 and $4.94 during the period. The latest price is near the upper end of the 7-day range, indicating moderate downward.
The average daily volume was 109.93 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
CING 52-Week Price Position
Position in Range: 17.2%
CING is currently trading at $4.66, placing it 17.2% of the way from its 52-week low of $3.16 to its 52-week high of $11.89. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Cingulate Inc. (CING)?
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
Cingulate Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 14 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Cingulate Inc. (CING) Stock on MEXC
Eligible investors can buy real shares of Cingulate Inc. (CING) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Cingulate Inc. (CING) stock price today?
2.Is CING stock going up or down today?
3.What is CING pre-market price?
4.What is CING after-hours price?
5.Is CING stock trading now?
6.Where does CING sit relative to its 52-week high and low?
7.What sector is Cingulate Inc. in?
8.What is Cingulate Inc.'s market capitalization and where is it listed?
9.How is CING valued in terms of P/E ratio and EPS?
10.Does Cingulate Inc. pay a dividend?
Explore More US Stocks
Search Stocks
CING Stock Calculator
Estimate the value between CING shares and USD.
CING Shares to USD
1.00 CING shares = 4.663 USD
Calculations are estimates based on the latest available price and are for reference only.


